Download PDF
Laryngorhinootologie 2019; 98(01): 48-59
DOI: 10.1055/a-0588-9400
Facharztwissen HNO
© Georg Thieme Verlag KG Stuttgart · New York

Merkelzellkarzinome der Kopf-Hals-Region

Head & Neck Merkel Cell Carcinoma
Teresa B. Steinbichler
,
Undine Hauser
,
Volker H. Schartinger
,
József Dudás
,
Herbert Riechelmann
Further Information

Publication History

Publication Date:
13 July 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Merkelzellkarzinome (MCC) sind hochmaligne neuroendokrine Tumore der Haut. Auch wenn sie sehr selten sind, hat sich ihre Inzidenz in den letzten 20 Jahren verdoppelt. Ihre Mortalität ist höher als die des malignen Melanoms. Risikofaktor ist neben UV-Exposition eine iatrogene oder anderweitige Immunsuppression. MCC betreffen vor allem Menschen jenseits des 70. Lebensjahrs und treten in der Hälfte der Fälle in der Kopf-Hals-Region auf.

Abstract

Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin. Even if it is quite rare, the incidence has increased about two fold during the last twenty years. Mortality is higher than in malignant melanoma. Risk factors are chronic UV exposition and immunosuppression. MCC are most common in patients over 70 years and half of them manifest in the head and neck region. They early metastasize to regional lymph nodes. Surgical therapy should include wide resection of the primary tumor and diagnostic lymph node excision. In the head and neck region this means usually ipsilateral selective neck dissection. Adjuvant radiotherapy of the primary tumor bed and associated lymph nodes of the head and neck region decreases recurrence and should be performed in every patient regardless of the T- and N-stage. In the head and neck region adjuvant radiotherapy can only be spared in selected patients with low-risk profile (wide excisional margins > 2 cm, primary tumor size > 1 cm, absent lymphovascular infiltration, no immunosuppression and pathologic negative cervical lymph nodes). Isolated radiotherapy or systemic therapies are usually applied in patients with metastasized MCC. Disease recurrence is most common in the first two years after initial diagnosis. Patients should be examined at short intervals during this time.

Schlüsselwörter

Merkel-Zellen - Hauttumoren - Kopf-Hals-Region - Karzinom

Key words

head - neck - Merkel Cells - Carcinoma - skin tumor
 

  • Literatur

  • 1 Erovic I, Erovic BM. Merkel cell carcinoma: the past, the present, and the future. J Skin Cancer 2013; 2013: 929364
    PubMedGoogle Scholar
  • 2 Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105 (01) 107-110
    CrossrefPubMedGoogle Scholar
  • 3 Tang CK, Toker C, Nedwich A. et al. Unusual cutaneous carcinoma with features of small cell (oat cell-like) and squamous cell carcinomas. A variant of malignant Merkel cell neoplasm. Am J Dermatopathol 1982; 4 (06) 537-548
    CrossrefPubMedGoogle Scholar
  • 4 Becker JC. Merkel cell carcinoma. Ann Oncol 2010; 21 (Suppl. 07) vii81-85
    CrossrefPubMedGoogle Scholar
  • 5 Andea AA, Coit DG, Amin B. et al. Merkel cell carcinoma: histologic features and prognosis. Cancer 2008; 113 (09) 2549-2558
    CrossrefPubMedGoogle Scholar
  • 6 Becker JC, Stang A, DeCaprio JA. et al. Merkel cell carcinoma. Nat Rev Dis Primers 2017; 3: 17077
    CrossrefPubMedGoogle Scholar
  • 7 Wong HH, Wang J. Merkel cell carcinoma. Arch Pathol Lab Med 2010; 134 (11) 1711-1716
    CrossrefPubMedGoogle Scholar
  • 8 Houben R, Schrama D, Becker JC. Molecular pathogenesis of Merkel cell carcinoma. Exp Dermatol 2009; 18 (03) 193-198
    CrossrefPubMedGoogle Scholar
  • 9 Agelli M, Clegg LX, Becker JC. et al. The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer 2010; 34 (01) 14-37
    CrossrefPubMedGoogle Scholar
  • 10 Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993–2007. Eur J Cancer 2011; 47 (04) 579-585
    CrossrefPubMedGoogle Scholar
  • 11 Fields RC, Busam KJ, Chou JF. et al. Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg 2011; 254 (03) 465-473 discussion 73–75
    CrossrefPubMedGoogle Scholar
  • 12 Fields RC, Busam KJ, Chou JF. et al. Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer 2012; 118 (13) 3311-3320
    CrossrefPubMedGoogle Scholar
  • 13 Veness MJ, Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol 2007; 51 (01) 12-20
    CrossrefPubMedGoogle Scholar
  • 14 Becker JC, Vordermark D, Reske SN. et al. S2k 032/023 Leitlinie: Merkelzellkarzinome. AWMF Online; 2012
    PubMedGoogle Scholar
  • 15 Popp S, Waltering S, Herbst C. et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002; 99 (03) 352-360
    CrossrefPubMedGoogle Scholar
  • 16 Banks PD, Sandhu S, Gyorki DE. et al. Recent Insights and Advances in the Management of Merkel Cell Carcinoma. J Oncol Pract 2016; 12 (07) 637-646
    CrossrefPubMedGoogle Scholar
  • 17 Martel-Jantin C, Pedergnana V, Nicol JT. et al. Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. J Clin Virol 2013; 58 (01) 288-291
    CrossrefPubMedGoogle Scholar
  • 18 Lill C, Schneider S, Item CB. et al. P53 mutation is a rare event in Merkel cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 2011; 268 (11) 1639-1646
    CrossrefPubMedGoogle Scholar
  • 19 Heath M, Jaimes N, Lemos B. et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58 (03) 375-381
    CrossrefPubMedGoogle Scholar
  • 20 Network NCC. NCCN Guidelines Version 1.2018 Merkel Cell Carcinoma: NCCN 2017, updated 09/18/2017. Version 1.2018
    PubMedGoogle Scholar
  • 21 Enzenhofer E, Ubl P, Czerny C. et al. Imaging in patients with merkel cell carcinoma. J Skin Cancer 2013; 2013: 973123
    PubMedGoogle Scholar
  • 22 George A, Girault S, Testard A. et al. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution. Nucl Med Commun 2014; 35 (03) 282-290
    CrossrefPubMedGoogle Scholar
  • 23 UICC. TNM Klassifikation maligner Tumoren. Christian W. editor Weinheim, Germany: Wiley-VCH; 2017
    Google Scholar
  • 24 Fritsch P. Dermatologie. Berlin, Heidelberg: Springer; 2003
    Google Scholar
  • 25 Santamaria-Barria JA, Boland GM, Yeap BY. et al. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 2013; 20 (04) 1365-1373
    CrossrefPubMedGoogle Scholar
  • 26 Poulsen M, Round C, Keller J. et al. Factors influencing relapse-free survival in Merkel cell carcinoma of the lower limb--a review of 60 cases. Int J Radiat Oncol Biol Phys 2010; 76 (02) 393-397
    CrossrefPubMedGoogle Scholar
  • 27 Kline L, Coldiron B. Mohs Micrographic Surgery for the Treatment of Merkel Cell Carcinoma. Dermatol Surg 2016; 42 (08) 945-951
    CrossrefPubMedGoogle Scholar
  • 28 Lebbe C, Becker JC, Grob JJ. et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51 (16) 2396-2403
    CrossrefPubMedGoogle Scholar
  • 29 Ghadjar P, Kaanders JH, Poortmans P. et al. The essential role of radiotherapy in the treatment of Merkel cell carcinoma: a study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2011; 81 (04) e583-e591
    CrossrefPubMedGoogle Scholar
  • 30 Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017 Mar 9. doi: 10.1097/CCO.0000000000000363
    PubMedGoogle Scholar
  • 31 Brower V. Pembrolizumab in advanced head and neck cancer. Lancet Oncol 2017; 18 (05) e248
    CrossrefPubMedGoogle Scholar
  • 32 Kaufman HL, Russell J, Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17 (10) 1374-1385
    CrossrefPubMedGoogle Scholar
  • 33 Barkdull S, Brownell I. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma. Cancer Biol Ther 2017; 18 (12) 937-939
    CrossrefPubMedGoogle Scholar
  • 34 Nguyen VA. Praxisverändernde Studien bei Melanom und Merkelzellkarzinom, ESMO 2017. Kinderkrebshilfe 2017; 10
    PubMedGoogle Scholar
  • 35 Iyer JG, Blom A, Doumani R. et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 2016; 5 (09) 2294-2301
    CrossrefPubMedGoogle Scholar
  • 36 Nghiem P, Kaufman HL, Bharmal M. et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 2017; 13 (14) 1263-1279
    CrossrefPubMedGoogle Scholar
  • 37 Colunga A, Pulliam T, Nghiem P. Merkel cell carcinoma in the age of immunotherapy: Facts and hopes. Clin Cancer Res 2018; 24 (09) 2035-2043
    CrossrefPubMedGoogle Scholar
  • 38 Fochtmann A, Haymerle G, Kunstfeld R. et al. Prognostic significance of lymph node ratio in patients with Merkel cell carcinoma. Eur Arch Otorhinolaryngol 2015; 272 (07) 1777-1783
    CrossrefPubMedGoogle Scholar
  • 39 Paulson KG, Iyer JG, Tegeder AR. et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29 (12) 1539-1546
    CrossrefPubMedGoogle Scholar
  • 40 Vujic I, Marker M, Posch C. et al. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression. J Eur Acad Dermatol Venereol 2015; 29 (03) 542-548
    CrossrefPubMedGoogle Scholar
  • 41 Bhatia K, Goedert JJ, Modali R. et al. Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome. Int J Cancer 2010; 127 (06) 1493-1496
    PubMedGoogle Scholar
  • 42 Paulson KG, Carter JJ, Johnson LG. et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 2010; 70 (21) 8388-8397
    CrossrefPubMedGoogle Scholar
  • 43 Girschik J, Thorn K, Beer TW. et al. Merkel cell carcinoma in Western Australia: a population-based study of incidence and survival. Br J Dermatol 2011; 165 (05) 1051-1057
    CrossrefPubMedGoogle Scholar
  • 44 Lemos BD, Storer BE, Iyer JG. et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010; 63 (05) 751-761
    CrossrefPubMedGoogle Scholar